Related Experiment Video

Updated: May 7, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.3K

Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin-1-Mediated PI3K/AKT Signaling Pathway in

Yujia Zhou1, Hejing Liu1, Shuangjia Pan1

  • 1Zhejiang Provincial Clinical Research Center for Gynecological Diseases, Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|May 6, 2026
PubMed

Insights

Simvastatin enhances cisplatin chemotherapy effectiveness in resistant cervical cancer by downregulating caveolin-1 and the PI3K/AKT pathway. This combination therapy offers a promising strategy to overcome drug resistance and improve patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Cisplatin resistance is a major challenge in cervical cancer treatment.
  • Statins show potential anti-tumor and chemosensitizing effects beyond lipid-lowering.
  • The role of statins in overcoming cisplatin resistance in cervical cancer requires clarification.

Purpose of the Study:

  • To investigate the efficacy of seven statins in combination with cisplatin against cisplatin-resistant cervical cancer cells.
  • To elucidate the underlying molecular mechanisms of statin-mediated chemosensitization.

Main Methods:

  • CCK-8 assay to assess cell viability and IC50 values.
  • In vitro studies using cisplatin-resistant cervical cancer cell lines (SiHa-DDP, C33a-DDP).
  • In vivo studies using xenograft tumor models.
  • Western blot analysis to evaluate protein expression (CAV1, PI3K, p-AKT).
  • Caveolin-1 (CAV1) knockdown and overexpression experiments.

Main Results:

  • Simvastatin significantly enhanced cisplatin efficacy in resistant cells, showing synergistic effects.
  • Combined simvastatin and cisplatin treatment inhibited cell viability and migration, promoting apoptosis.
  • Simvastatin downregulated CAV1, PI3K, and p-AKT protein expression.
  • CAV1 knockdown increased cisplatin sensitivity, while its overexpression counteracted simvastatin's effects.
  • In vivo studies confirmed suppressed tumor growth and increased apoptosis with combination therapy.

Conclusions:

  • Simvastatin enhances cisplatin sensitivity in cervical cancer by suppressing the CAV1-mediated PI3K/AKT pathway.
  • Simvastatin represents a potential adjuvant therapy to improve cisplatin chemotherapy efficacy in resistant cervical cancer.
  • Targeting the CAV1/PI3K/AKT pathway offers a novel therapeutic strategy for overcoming cisplatin resistance.
Keywords:
Caveolin‐1PI3K/AKT signaling pathwaycervical cancercisplatin resistancesimvastatin

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.3K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
937
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
829
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.2K